Avidity Partners Management’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,174,700
| Closed | -$46.6M | – | 108 |
|
|
2024
Q1 | $46.6M | Buy |
+1,174,700
| New | +$34.7M | 1.5% | 22 |
|
|
2023
Q4 | – | Sell |
-657,280
| Closed | -$7.53M | – | 93 |
|
|
2023
Q3 | $7.53M | Sell |
657,280
-401,220
| -38% | -$4.94M | 0.3% | 70 |
|
|
2023
Q2 | $10.9M | Buy |
1,058,500
+69,000
| +7% | +$622K | 0.38% | 72 |
|
|
2023
Q1 | $7.64M | Sell |
989,500
-38,700
| -4% | -$308K | 0.25% | 67 |
|
|
2022
Q4 | $7.56M | Buy |
1,028,200
+29,600
| +3% | +$189K | 0.16% | 62 |
|
|
2022
Q3 | $7.19M | Buy |
998,600
+35
| +0% | +$288 | 0.15% | 72 |
|
|
2022
Q2 | $8.5M | Sell |
998,565
-208,435
| -17% | -$1.8M | 0.2% | 52 |
|
|
2022
Q1 | $10.8M | Sell |
1,207,000
-138,000
| -10% | -$1.19M | 0.23% | 61 |
|
|
2021
Q4 | $18.6M | Sell |
1,345,000
-587,000
| -30% | -$7.27M | 0.4% | 57 |
|
|
2021
Q3 | $20.6M | Buy |
1,932,000
+437,000
| +29% | +$4.03M | 0.46% | 53 |
|
|
2021
Q2 | $13.5M | Sell |
1,495,000
-16,000
| -1% | -$174K | 0.36% | 62 |
|
|
2021
Q1 | $16M | Buy |
1,511,000
+263,000
| +21% | +$3.28M | 0.44% | 65 |
|
|
2020
Q4 | $15.7M | Buy |
1,248,000
+438,000
| +54% | +$4.3M | 0.51% | 55 |
|
|
2020
Q3 | $7.12M | Buy |
+810,000
| New | +$7.41M | 0.33% | 52 |
|
Avidity Partners Management's ALPN Position: Q2 2024 in Review
Avidity Partners Management sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 1,174,700 shares — an estimated $46.6M sold.
Avidity Partners Management first reported a position in ALPN in Q3 2020 and held it in 14 quarters. The position peaked at $46.6M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Avidity Partners Management reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Avidity Partners Management sold 1,174,700 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $46.6M.
- Avidity Partners Management first reported a position in Alpine Immune Sciences Inc in Q3 2020 and held it in 14 quarters.
- Avidity Partners Management's Alpine Immune Sciences Inc position peaked at $46.6M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.